EASL 2025指征再评估:慢性乙肝不同分期接受或未接受核苷(酸)类似物治疗的结局
OBJECTIVE: The impact of nucleos(t)ide analogues (NAs) therapy on the long-term outcomes in chronic HBV infection individuals outside 2025 European Association for the Study of the Liver (EASL) strongly recommended treatment indications remains uncertain.…
要点
- HBeAg阳性高复制期接受NAs治疗与肝硬化风险降低相关(HR 0.18)。
- HBeAg阳性高复制期接受NAs治疗与HCC风险降低相关(HR 0.03)。
- HBeAg阴性低复制或高复制低风险者接受NAs治疗未见显著关联。
核心结论
- 在2025 EASL强推荐治疗指征外的HBeAg阳性高复制或即将进入过渡期人群中,NAs治疗与肝硬化及HCC风险降低相关,支持扩大慢性HBV感染治疗指征。
主要发现
- 随访期间共记录635例新发肝硬化和164例HCC。
- 第1组(HBeAg阳性高复制)接受NAs治疗者肝硬化风险HR 0.18(95%CI 0.11–0.32),HCC风险HR 0.03(95%CI 0.01–0.21)。
- 第2组(HBeAg阳性即将进入过渡期)接受NAs治疗者肝硬化风险HR 0.50(95%CI 0.41–0.61),HCC风险HR 0.25(95%CI 0.16–0.41)。
- 第3组(HBeAg阴性低复制)和第4组(HBeAg阴性高复制低风险)中未观察到NAs治疗与肝硬化或HCC风险的显著关联。
- 倾向性评分匹配分析结果与主分析一致。
关键数值与推荐
- 第1组定义:HBeAg阳性、高复制(年龄<30岁、HBV DNA≥8 log₁₀IU/mL、ALT正常、无或轻度纤维化、无肝癌家族史)。
- 第2组定义:HBeAg阳性、即将进入过渡期(通常年龄≥30岁、HBV DNA≥6 log₁₀IU/mL、ALT正常、无进展期纤维化)。
- 第3组定义:HBeAg阴性、低复制(HBV DNA<3.3 log₁₀IU/mL、ALT正常、无或轻度纤维化)。
- 第4组定义:HBeAg阴性、高复制低风险(HBV DNA 3.3–4.3 log₁₀IU/mL、ALT正常、无或轻度纤维化)。
临床怎么用
- 对于2025 EASL强推荐治疗指征外的HBeAg阳性高复制或即将进入过渡期患者,可考虑启动NAs治疗以降低肝硬化和HCC风险。
- 对于HBeAg阴性低复制或高复制低风险患者,NAs治疗的获益尚不明确,需个体化评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The impact of nucleos(t)ide analogues (NAs) therapy on the long-term outcomes in chronic HBV infection individuals outside 2025 European Association for the Study of the Liver (EASL) strongly recommended treatment indications remains uncertain. We aimed to assess the association between NAs therapy and the risks of cirrhosis and hepatocellular carcinoma (HCC) in Chinese chronic HBV infection individuals outside these criteria. DESIGN: We analysed data from 30 784 chronic HBV infection individuals across 12 centres in China. We categorised individuals outside 2025 EASL strongly recommended treatment criteria into four groups: (1) hepatitis B e antigen (HBeAg)-positive, high replicative (age <30, HBV DNA ≥8 log₁₀IU/mL, normal alanine aminotransferase (ALT), no/mild fibrosis, no family history of liver cancer); (2) HBeAg-positive, impending phase transition (typically age ≥30, HBV DNA ≥6 log₁₀IU/mL, normal ALT, no advanced fibrosis); (3) HBeAg-negative, low replicative (HBV DNA <3.3 log₁₀IU/mL, normal ALT, no/mild fibrosis); (4) HBeAg-negative, high replicative, low-risk (HBV DNA 3.3-4.3 log₁₀IU/mL, normal ALT, no/mild fibrosis). The primary endpoints were the incidence of cirrhosis and HCC. RESULTS: Up to 5 years of follow-up (117 814 person-years), we documented 635 incident cirrhosis and 164 HCC cases. In multivariable analyses, NA therapy significantly reduced risks of cirrhosis (HR 0.18, 95% CI 0.11 to 0.32) and HCC (HR 0.03, 95% CI 0.01 to 0.21) in Group 1, and cirrhosis (HR 0.50, 95% CI 0.41 to 0.61) and HCC (HR 0.25, 95% CI 0.16 to 0.41) in Group 2. No significant associations were observed in Groups 3 and 4. Findings were consistent in propensity score matching analyses. CONCLUSION: NAs therapy was associated with reduced risks of cirrhosis and HCC in HBeAg-positive individuals with high replicative or impending phase transition phenotypes, supporting the expansion of chronic HBV infection treatment criteria.
引用
- Tang S, Huang T, Tang R, et al. EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection. Gut. 2026. PMID: 41151792. doi:10.1136/gutjnl-2025-335449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。